Myotonic Dystrophy Type 2 Clinical Trials

Find Myotonic Dystrophy Type 2 Clinical Trials Near You

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 (SRP-1003) in Subjects With Type 1 Myotonic Dystrophy Who Are ≥18 to ≤ 65 Years

Status: Recruiting
Location: See all (35) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is a phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of single and multiple ascending doses of SRP-1003 compared to placebo in male and female participants with type 1 myotonic dystrophy (DM1). Participants who have provided written informed consent and met all protocol eligibility requirements will be randomized to receive single (Part 1) or multiple (Part 2) doses of SRP-1003 or placebo.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Genetically confirmed diagnosis of DM1

• Clinician-assessed signs of DM1 including clinically apparent myotonia

• Onset of DM1 symptoms occurred after the age of 12 years

• Walk for at least 10 meters independently at screening

• Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last dose of study drug, whichever is later. Participants must not donate sperm or eggs during the study and for at least 90 days following the end of study or last dose of study drug whichever is later.

Locations
Other Locations
Australia
Sunshine Coast University Hospital
RECRUITING
Birtinya
Nucleus Network Brisbane Clinic
RECRUITING
Herston
Royal Brisbane And Women's Hospital
RECRUITING
Herston
Liverpool Hospital
RECRUITING
Liverpool
Alfred Health
RECRUITING
Melbourne
Mater Hospital Brisbane
RECRUITING
South Brisbane
Belgium
Universitair Ziekenhuis Gent
RECRUITING
Ghent
UZ Leuven
RECRUITING
Leuven
Canada
University Of Calgary
RECRUITING
Calgary
University Of Alberta
RECRUITING
Edmonton
McGill University
RECRUITING
Montreal
France
University Hospital of Angers
RECRUITING
Angers
Centre Hospitalier Universitaire De Bordeaux
RECRUITING
Bordeaux
Centre Hospitalier Universitaire De Lille
RECRUITING
Lille
CHU de Nice - Hôpital Pasteur 2
RECRUITING
Nice
Assistance Publique Hôpitaux De Paris
RECRUITING
Paris
Germany
Klinikum der Universität München AöR
RECRUITING
Munich
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.
RECRUITING
Ulm
Italy
Fondazione Serena Onlus - Centro Clinico Nemo Brescia
RECRUITING
Gussago
Centro Clinico Nemo (Milan)
RECRUITING
Milan
Azienda Ospedaliera Universitaria Pisana (AOUP)
RECRUITING
Pisa
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING
Roma
New Zealand
New Zealand Clinical Research Christchurch
RECRUITING
Christchurch
Spain
Hospital Universitario Torrecárdenas
RECRUITING
Almería
Hospital Universitari Vall D Hebron
RECRUITING
Barcelona
Hospital Universitario Infanta Sofia
RECRUITING
Madrid
Taiwan
China Medical University Hospital
RECRUITING
Taichung
National Taiwan University Hospital
RECRUITING
Taipei
Taipei Veterans General Hospital
RECRUITING
Taipei
Thailand
Siriraj Hospital
RECRUITING
Bangkok
Songklanagarind Hospital
RECRUITING
Hat Yai
Lampang Hospital
RECRUITING
Lampang
United Kingdom
The National Hospital for Neurology and Neurosurgery, NHS Foundation Trust
RECRUITING
London
Nottingham University Hospitals NHS Trust
RECRUITING
Nottingham
Southampton General Hospital, NHS Foundation Trust
RECRUITING
Southampton
Contact Information
Primary
Sarepta Therapeutics Inc. For Clinical Trial Information, Select Option 4
SareptAlly@sarepta.com
1-888-SAREPTA (1-888-727-3782)
Time Frame
Start Date: 2024-03-04
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 78
Treatments
Experimental: SRP-1003 IV Infusion
Single or multiple doses of SRP-1003 by intravenous (IV) infusion
Placebo_comparator: Placebo by IV Infusion
Single or multiple doses of placebo by IV infusion
Experimental: SRP-1003 SC Injection
Single or multiple doses of SRP-1003 by subcutaneous (SC) injection
Placebo_comparator: Placebo by SC Injection
Single or multiple doses of placebo by SC injection
Sponsors
Leads: Sarepta Therapeutics, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials